Naftopidil in the Management of BPH
May 1, 2013
Naftopidil has affinity for both α1A- and α1D-adrenoreceptors for the treatment of benign prostatic obstruction and benign prostatic hyperplasia (BPH) associated with lower urinary tract symptoms (LUTS). It was originally developed as an α-adrenoceptor antagonistic anti-hypertensive drug. It has been evaluated in both prazosin-controlled and double-blind-controlled trials in Japan that verified dose-dependent effects, and therefore has had an indication for treatment of BPH in Japan, China, and South Korea. Several tamsulosin-controlled trials have suggested a potentially higher efficacy for alleviating storage symptoms with naftopidil. The optimal dose is 50-75mg per day according to characteristics including baseline IPSS. Well-designed randomized trials are warranted to confirm long-term outcomes regarding management of men with storage symptoms including nocturia, through comparisons of quality of life measures with other α-adrenergic blockers.
Reference: Hara N, Mizusawa T, Obara K, Takahashi K. The role of naftopidil in the management of benign prostatic hyperplasia. Ther Adv Urol 2013;5(2)111-119.
Why do men tolerate bothersome urinary symptoms rather than seek medical advice?
September 30, 2011
Many men over the age of 50 experience clinical (or symptomatic) benign prostatic hyperplasia (BPH), but often delay in speaking to a healthcare professional about the bothersome urinary symptoms that accompany this condition.1,2 Why do men tolerate these symptoms? To answer this question, GlaxoSmithKline (GSK) has funded The BPH survey: a male perspective, a European survey that aims to reveal male attitudes and behaviours towards bothersome urinary symptoms.
Professor Siegfried Meryn, General Secretary of the International Society of Men's Health, explains:
“Male attitudes towards urinary symptoms have been neglected in medical research and this is one of the very few surveys that asks ‘how do men feel?' and ‘why don't men seek help?' This survey will provide a unique insight about men and their health and it is vital that we, as healthcare professionals, understand the attitudes and behaviours of the men we are treating.”
The BPH survey: a male perspective was developed by an expert steering group of urologists and GPs, and explores:
- What discourages men from seeking medical attention
- What prompts men to seek help
- Who men consult about their bothersome urinary symptoms
It is hoped that the insights will help healthcare professionals have more meaningful conversations with men about their prostate problems so that their condition can be rapidly diagnosed and managed. Findings from the survey should also help men to understand that bothersome urinary symptoms are not an inevitable part of ageing.
GlaxoSmithKline (GSK) is committed to supporting research to help educate and increase understanding of Benign Prostatic Hyperplasia (BPH), a common prostate disorder. As part of this commitment GSK has developed and funded this project – “The BPH survey: a male perspective” through the creation of a steering group of healthcare professionals – urologists and GPs – to advise on the content of the survey, as well as the implementation of the project across the largest European markets (UK, France, Italy, Germany and Spain). GSK has supported and paid the International Society of Men´s Health (ISMH) for the opportunity to launch the results of this project in the press contact section of their website during their annual Men´s Health World Congress, taking place in Vienna in 2011. All rights relating to the project and the data published are property of GSK.
1. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991; 338: 469-71.
2. Banks I, Mayor S, Meryn S. Talking prostates. Journal of Men's Health. 2010; 7: 221-226.
Date of preparation: September 2011 , Job bag code: URCE/BPH/0022a/11